Current concepts in the pathogenesis and interval treatment of migraine.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001920:Bradykinin / Q000378:metabolism; D003000:Clonidine / Q000627:therapeutic use; D003508:Cycloheptanes / Q000627:therapeutic use; D003533:Cyproheptadine / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D006632:Histamine / Q000097:blood / Q000378:metabolism; D006801:Humans; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D011453:Prostaglandins / Q000378:metabolism; D012701:Serotonin / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D012702:Serotonin Antagonists; D013876:Thiophenes / Q000627:therapeutic use; D014439:Tyramine / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D003508:Cycloheptanes; D010880:Piperidines; D011453:Prostaglandins; D012702:Serotonin Antagonists; D013876:Thiophenes; D003533:Cyproheptadine; D012701:Serotonin; D006632:Histamine; D003000:Clonidine; D004878:Ergotamine; D001920:Bradykinin; D009638:Norepinephrine; D014439:Tyramine; D008784:Methysergide